Cite
Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double‐blind, placebo‐controlled study.
MLA
Metz, Martin, et al. “Omalizumab Normalizes the Gene Expression Signature of Lesional Skin in Patients with Chronic Spontaneous Urticaria: A Randomized, Double‐blind, Placebo‐controlled Study.” Allergy, vol. 74, no. 1, Jan. 2019, pp. 141–51. EBSCOhost, https://doi.org/10.1111/all.13547.
APA
Metz, M., Torene, R., Kaiser, S., Beste, M. T., Staubach, P., Bauer, A., Brehler, R., Gericke, J., Letzkus, M., Hartmann, N., Erpenbeck, V. J., & Maurer, M. (2019). Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double‐blind, placebo‐controlled study. Allergy, 74(1), 141–151. https://doi.org/10.1111/all.13547
Chicago
Metz, Martin, Rebecca Torene, Sergio Kaiser, Michael T. Beste, Petra Staubach, Andrea Bauer, Randolf Brehler, et al. 2019. “Omalizumab Normalizes the Gene Expression Signature of Lesional Skin in Patients with Chronic Spontaneous Urticaria: A Randomized, Double‐blind, Placebo‐controlled Study.” Allergy 74 (1): 141–51. doi:10.1111/all.13547.